NORTHERN SYDNEY AND CENTRAL COAST AREA HEALTH SERVICE

Foresee Pharmaceuticals to Present Phase 3 KATANA Studies of Novel Prostate Cancer Treatment at ASCO-GU 2025

3 months ago

• Foresee Pharmaceuticals will present data from their Phase 3 KATANA studies evaluating FP-014, a novel triptorelin mesylate injection for advanced prostate cancer, at the 2025 ASCO-GU Symposium. • The studies investigate two formulations: an 11.25 mg quarterly injection and a 22.5 mg semi-annual injection, aiming to become the first ready-to-use triptorelin long-acting injectable. • The presentation highlights Foresee's SIF-LAI technology platform and its potential to develop best-in-class long-acting injectables for cancer treatment.

Aethlon Medical Treats First Patient in Hemopurifier Solid Tumor Trial

6 months ago

• Aethlon Medical has enrolled and treated the first patient in its Australian clinical trial of the Hemopurifier device for solid tumors. • The trial focuses on patients with stable or progressive disease despite anti-PD-1 monotherapy like pembrolizumab or nivolumab. • The Hemopurifier aims to improve response rates by removing tumor-derived extracellular vesicles (EVs) from the bloodstream. • The study's primary endpoint is safety, with secondary measures evaluating changes in EV concentrations and anti-tumor T cell activity.

Regorafenib Shows Survival Benefit in Late-Stage Gastric Cancer INTEGRATE IIa Trial

7 months ago

• Phase 3 INTEGRATE IIa trial demonstrates regorafenib extends median overall survival to 4.5 months versus 4.0 months with placebo in refractory advanced gastric/GEJ cancer patients. • Treatment with regorafenib significantly delayed disease progression and quality-of-life deterioration, with a progression-free survival of 1.8 months compared to 1.6 months for placebo. • The study validates regorafenib's potential as a treatment platform, supporting its investigation in combination therapies including ongoing trials with nivolumab and chemotherapy.

New Podcast 'Kidney Compass' Launches to Navigate Complex Landscape of Nephrology Clinical Trials

7 months ago

• Leading nephrologists Brendon Neuen and Shikha Wadhwani launch 'Kidney Compass,' a new podcast dedicated to demystifying clinical trials in nephrology for healthcare professionals. • The podcast aims to address rapid advancements in therapies for glomerular disease and diabetic kidney disease, while exploring evolving standards of care and trial design complexities. • Future episodes will feature prominent trialists and provide in-depth coverage of nephrology research, including planned coverage of ASN Kidney Week 2024.

Long-term efficacy and safety of iptacopan in PNH with anaemia

a year ago

The article discusses the long-term efficacy and safety of iptacopan, a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with anaemia, as presented by Prof. Antonio Risitano from the University of Naples, Italy.

Ponatinib Dose-Ranging Study Shows Efficacy in Chronic-Phase CML Patients

4 years ago

A phase 2 trial evaluating ponatinib in chronic-phase chronic myeloid leukemia (CP-CML) patients resistant to prior tyrosine kinase inhibitors (TKIs) demonstrated significant efficacy across three starting doses. The study highlighted a novel, response-based dose-reduction strategy, with the 45 mg starting dose showing optimal benefit/risk outcomes when reduced to 15 mg upon achieving a response.